Editorial: Advanced genomic techniques for congenital adrenal hyperplasia
-
By
-
Semra Çetinkaya
-
Henrik Falhammar
-
June 17, 2026
-
Clinical Scorecard: Innovative Genomic Approaches in the Study of Congenital Adrenal Hyperplasia
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Genetic complexities and advanced genomic techniques like Sanger sequencing, MLPA, and LRS for diagnosis and treatment. |
| Target Population | |
| Care Setting | |
Key Highlights
- 21OHD is the most common type of CAH, linked to the CYP21A2 locus, with diagnostic challenges due to genetic heterogeneity.
- Advanced genomic techniques like LRS and CRISPR/Cas9 are being explored for diagnosis and treatment, with LRS proposed as a future reference method.
- Circulating miRNA profiles provide insights into disease progression and treatment response, influenced by glucocorticoid therapy.
- Gene editing technologies may offer permanent cures for CAH by targeting adrenocortical progenitor cells, but carry risks of off-target effects.
- TNX haploinsufficiency is associated with CAH-X syndrome, linking connective tissue disorders with CAH.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
- Be aware of potential off-target effects and immunogenicity associated with gene editing technologies, including risks of oncogenesis.
Patient & Prescribing Data
Glucocorticoid therapy affects miRNA expression, with specific miRNAs showing differential regulation based on glucocorticoid dosage.
Clinical Best Practices
- Implement advanced genomic techniques for precise diagnosis and personalized treatment.
- Monitor miRNA profiles as potential biomarkers for treatment optimization, as they provide critical information on disease progression.
Related Resources & Content
